尚荣医疗
(002551)
| 流通市值：22.06亿 | | | 总市值：30.52亿 |
| 流通股本：6.11亿 | | | 总股本：8.45亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 753,521,493.62 | 528,042,409.63 | 279,741,529.44 | 1,448,206,268.39 |
| 营业收入 | 753,521,493.62 | 528,042,409.63 | 279,741,529.44 | 1,448,206,268.39 |
| 二、营业总成本 | 804,037,290.47 | 554,274,104.42 | 283,907,062.28 | 1,385,050,001.21 |
| 营业成本 | 645,369,074.57 | 441,091,432.86 | 237,019,686.94 | 1,188,953,686.35 |
| 税金及附加 | 19,007,034.5 | 14,733,612.24 | 5,724,769.63 | 22,465,222.76 |
| 销售费用 | 12,783,009.78 | 8,725,117.65 | 3,821,439.95 | 16,073,186.74 |
| 管理费用 | 104,228,606.23 | 69,110,261.1 | 33,921,138.26 | 132,993,791.04 |
| 研发费用 | 26,438,636.82 | 20,173,329.07 | 10,064,345.68 | 40,783,991.67 |
| 财务费用 | -3,789,071.43 | 440,351.5 | -6,644,318.18 | -16,219,877.35 |
| 其中:利息费用 | 13,894,349.84 | 13,443,810.73 | 968,478.8 | 5,828,053.65 |
| 其中:利息收入 | 5,007,137.24 | 4,897,069.22 | 1,477,585.18 | 10,764,801.48 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -4,936,679.7 | -3,638,102.83 | -919,641.25 | 1,322,766.63 |
| 加:投资收益 | 10,204,894.94 | 7,087,511.07 | 2,964,577.49 | 2,701,178.47 |
| 资产处置收益 | 3,194.89 | 3,104.67 | 3,106.5 | 124,830.39 |
| 资产减值损失(新) | 10,364.86 | 10,253.94 | 9,916.72 | -9,154,823.65 |
| 信用减值损失(新) | 10,654,888.28 | 17,312,590.11 | 25,797,294.22 | -29,835,989.98 |
| 其他收益 | 2,967,763.12 | 1,733,681.91 | 900,757.74 | 5,223,044.58 |
| 四、营业利润 | -31,611,370.46 | -3,722,655.92 | 24,590,478.58 | 33,537,273.62 |
| 加:营业外收入 | 2,112,135 | 1,095,560.09 | 187,926.28 | 6,220,965.74 |
| 减:营业外支出 | 569,793.26 | 393,715.98 | 242,222.25 | 6,154,699.75 |
| 五、利润总额 | -30,069,028.72 | -3,020,811.81 | 24,536,182.61 | 33,603,539.61 |
| 减:所得税费用 | 4,591,622.42 | 1,499,341.75 | 7,489,988.41 | 7,691,020.41 |
| 六、净利润 | -34,660,651.14 | -4,520,153.56 | 17,046,194.2 | 25,912,519.2 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -34,660,651.14 | -4,520,153.56 | 17,046,194.2 | 25,912,519.2 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -35,125,254.33 | -7,758,226.19 | 13,964,187.65 | 22,281,952.68 |
| 少数股东损益 | 464,603.19 | 3,238,072.63 | 3,082,006.55 | 3,630,566.52 |
| 扣除非经常损益后的净利润 | -42,325,482.07 | -12,518,689.29 | 11,703,692.54 | 11,658,106.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.04 | -0.01 | 0.02 | 0.03 |
| (二)稀释每股收益 | -0.04 | -0.01 | 0.02 | 0.03 |
| 八、其他综合收益 | -7,319,782.48 | -4,231,991.86 | -2,862,041.24 | 5,093,558.79 |
| 归属于母公司股东的其他综合收益 | -8,371,435.31 | -5,302,067.94 | -4,001,937.53 | 5,569,518.82 |
| 九、综合收益总额 | -41,980,433.62 | -8,752,145.42 | 14,184,152.96 | 31,006,077.99 |
| 归属于母公司股东的综合收益总额 | -43,496,689.64 | -13,060,294.13 | 9,962,250.12 | 27,851,471.5 |
| 归属于少数股东的综合收益总额 | 1,516,256.02 | 4,308,148.71 | 4,221,902.84 | 3,154,606.49 |
| 公告日期 | 2025-10-28 | 2025-08-26 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |